- Apollo Hospitals’ net income for the third quarter was 3.72 billion rupees, marking a 52% year-on-year increase, exceeding the estimate of 3.47 billion rupees.
- The company reported revenues of 55.3 billion rupees, a 14% rise from the previous year, though slightly below the estimate of 55.42 billion rupees.
- Healthcare services revenue reached 28 billion rupees, showing a 13% increase compared to the previous year.
- Diagnostics and retail health revenue was 3.9 billion rupees, up 15% year-on-year, nearly meeting the estimate of 3.91 billion rupees.
- Revenue from digital health and pharmacy distribution amounted to 23.5 billion rupees, increasing by 15% year-over-year, surpassing the estimate of 23.44 billion rupees.
- Total costs for the quarter were recorded at 50.6 billion rupees, which is a 12% increase from last year.
- The company earned other income of 638 million rupees, significantly up from 278 million rupees in the previous year.
- EBITDA was 7.62 billion rupees, slightly under the estimate of 7.71 billion rupees.
- A dividend of 9 rupees per share has been declared.
- Analyst ratings include 22 buys, 3 holds, and 4 sells.
Apollo Hospitals Enterprise on Smartkarma
On Smartkarma, independent analyst Tina Banerjee recently covered Apollo Hospitals Enterprise (APHS IN) with a bullish outlook in her report titled “Apollo Hospitals Enterprise (APHS IN): Upside Momentum to Continue on Promising Business Outlook.” According to the report, Apollo Hospitals expects a sequential improvement in Average Revenue Per Occupied Bed (ARPOB) with stronger growth in surgical volume and a better case mix. The company aims for a 100 basis points margin expansion over the next 3–4 quarters. In Q1FY25, Apollo Hospitals reported impressive results with a 15% revenue growth and an 83% surge in net profit. The EBITDA margin also improved to 13.3%, indicating positive momentum for the company in the upcoming quarters.
The analysis further highlights that Apollo Hospitals anticipates continuous improvement in Q2 and Q3, with an emphasis on enhancing volume growth, enhancing case and payer mix, and focusing on cost optimization to drive margin expansion. The company’s positive outlook is grounded in the belief that ARPOB growth will see sustained improvement in the coming quarters. With a strong focus on operational efficiency and revenue growth, Apollo Hospitals Enterprise appears poised for continued success based on the compelling insights provided by Tina Banerjee‘s research on Smartkarma.
A look at Apollo Hospitals Enterprise Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts from Smartkarma have provided insights into the long-term outlook for Apollo Hospitals Enterprise, based on their Smart Scores system. With a Growth score of 3 and a Momentum score of 4, the company is poised for solid expansion and is showing positive market momentum. This suggests that Apollo Hospitals Enterprise may have good potential for growth in the future.
Despite this positive outlook, the company’s Value, Dividend, and Resilience scores are more moderate. This indicates that while Apollo Hospitals Enterprise is showing growth and momentum, investors may need to consider other factors such as value and resilience when evaluating the company’s long-term prospects.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
